Volume 21 Issue 6
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(6): 977-980
HUANG Yuli, YAO Huiqiang, ZHANG Xianlin, XU Qiong, ZHOU Tong, WANG Dongmei, MIAO Anqi. Effect analysis of community chronic heart failure patients managed by stages under the guidance of third-class hospitals[J]. Chinese Journal of General Practice, 2023, 21(6): 977-980. doi: 10.16766/j.cnki.issn.1674-4152.003029
Citation: HUANG Yuli, YAO Huiqiang, ZHANG Xianlin, XU Qiong, ZHOU Tong, WANG Dongmei, MIAO Anqi. Effect analysis of community chronic heart failure patients managed by stages under the guidance of third-class hospitals[J]. Chinese Journal of General Practice, 2023, 21(6): 977-980. doi: 10.16766/j.cnki.issn.1674-4152.003029
shu

Effect analysis of community chronic heart failure patients managed by stages under the guidance of third-class hospitals

doi: 10.16766/j.cnki.issn.1674-4152.003029

  • Department of Cardiology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 SK2020A0351

  • Received Date: 2023-03-11
    Available Online: 2023-08-26
    Abstract
  •   Objective  Under the guidance of the team of the heart failure center of the third-class hospital, community doctors and nurses implemented target management for community patients with chronic heart failure by stages, and analyzed the target effect of management.  Methods  A total of 760 chronic heart failure patients aged 30-92 from four community health service centers in Bengbu City were selected from June to December in 2021. Community hospitals were guided by doctors from the Heart Failure Center of the First Affiliated Hospital of Bengbu Medical College to follow up and manage chronic heart failure in stages for one year. The main observation indicators included patient awareness of heart failure, standardized drug usage rate, standardized drug compliance rate, quality of life score, and annual hospitalization rate before and after management.  Results  The awareness rate of heart failure among patients increased (55.45% vs. 97.63%, χ2=178.031, P=0.002). The usage rate of β receptor blockers increased in heart failure patients (22.75% vs. 92.89%, χ2=296.121, P=0.001), the usage rate of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor and neprilysin inhibitor (ARNI) increased (46.21% vs. 90.28%, χ2=186.173, P=0.002), and the usage rate of spironolactone increased (63.27% vs. 91.70%, χ2=120.312, P=0.003). The compliance rate of β receptor blockers increased (5.92% vs. 83.65%, χ2=328.231, P=0.001), the compliance rate of ACEI/ARB/ARNI increased (12.56% vs. 82.70%, χ2=296.224, P=0.001), and the compliance rate of spironolactone increased (43.36% vs. 85.55%, χ2=178.321, P=0.002). The quality of life score improved (t=95.311, P=0.003), and the annual hospitalization rate decreased (45.50% vs. 24.41%, χ2=85.252, P=0.004).  Conclusion  Under the guidance of tertiary hospitals, the standardized management by stages for community chronic heart failure patients has improved the control rate and quality of life of heart failure patients, reduced readmission, and improved the level of heart failure prevention and treatment by community doctors, thus promoting the continuous implementation of graded diagnosis and treatment policies.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    莫然, 谭慧琼, 刘少帅, 等. 我国心力衰竭患者疾病认知程度的现况调查[J]. 中国循环杂志, 2020, 35(4): 355-360. doi: 10.3969/j.issn.1000-3614.2020.04.007

    MO R, TAN H Q, LIU S S, et al. Current Status on Knowledge of Heart Failure Among Heart Failure Patients in China[J]. Chinese Circulation Journal, 2020, 35(4): 355-360. doi: 10.3969/j.issn.1000-3614.2020.04.007
    [2]
    SHANI M, OZAN E, DUANI Y, et al. Survival benefit in patients with heart failure treated in specialized heart failure center within the community[J]. Isr Med Assoc J, 2020, 22(1): 8-12.
    [3]
    JAARSMA T, HILL L, BAYES-GENIS A, et al. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2021, 23(1): 157-174. doi: 10.1002/ejhf.2008
    [4]
    VENTURA H O, PIÑA I L. Heart failure management throughout the continuum[J]. Prog Cardiovasc Dis, 2020, 63(5): 537. doi: 10.1016/j.pcad.2020.09.008
    [5]
    中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004

    Heart Failure Group of Chinses Society of Cardiology of Chinses Medical Association, Chinses Heart Failure Association of Chinses Medical Doctor Association, Editorial Board of Chinses Journar of Cardioloy. Chinese Guidelines for the diagnosis and treatment of heart Failure 2018[J]. Chinese Journal of Cardiology, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
    [6]
    CATCHPOOL M, RAMCHAND J, HARE D L, et al. Mapping the minnesota living with heart failure questionnaire (MLHFQ) onto the assessment of quality of life 8D (AQoL-8D) utility scores[J]. Qual Life Res, 2020, 29(10): 2815-2822. doi: 10.1007/s11136-020-02531-4
    [7]
    WANG Z R, ZHOU J W, LIU X P, et al. Effects of WeChat platform-based health management on health and self-management effectiveness of patients with severe chronic heart failure[J]. World J Clin Cases, 2021, 9(34): 10576-10584. doi: 10.12998/wjcc.v9.i34.10576
    [8]
    LANS C, CIDER Å, NYLANDER E, et al. The relationship between six-minute walked distance and health-related quality of life in patients with chronic heart failure[J]. Scand Cardiovasc J, 2022, 56(1): 310-315. doi: 10.1080/14017431.2022.2107234
    [9]
    GRIFFIN M, SOUFER A, GOLJO E, et al. Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center ' s experience[J]. JACC Heart Fail, 2020, 8(3): 199-208. doi: 10.1016/j.jchf.2019.10.012
    [10]
    AIMO A, PATERAS K, STAMATELOPOULOS K, et al. Relative Efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis[J]. Cardiovasc Drugs Ther, 2021, 35(5): 1067-1076. doi: 10.1007/s10557-020-07099-2
    [11]
    VADUGANATHAN M, CLAGGETT B L, DESAI A S, et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF[J]. J Am Coll Cardiol, 2020, 75(3): 245-254. doi: 10.1016/j.jacc.2019.11.003
    [12]
    BOWLES N P, THOSAR S S, HERZIG M X, et al. Correction to: chronotherapy for hypertension[J]. Curr Hypertens Rep, 2018, 21(1): 1.
    [13]
    LYON A R, DENT S, STANWAY S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society[J]. Eur J Heart Fail, 2020, 22(11): 1945-1960. doi: 10.1002/ejhf.1920
    [14]
    KASHANI F, ABAZARI P, HAGHANI F. Challenges and strategies of needs assessment implementing in diabetes self-management education in iran: a qualitative study[J]. Iran J Nurs Midwifery Res, 2020, 25(5): 437-443. doi: 10.4103/ijnmr.IJNMR_10_20
    [15]
    TIOZZO S N, BASSO C, CAPODAGLIO G, et al. Effectiveness of a community care management program for multimorbid elderly patients with heart failure in the Veneto Region[J]. Aging Clin Exp Res, 2019, 31(2): 241-247. doi: 10.1007/s40520-018-1102-y
    [16]
    BRAY N, KOLEHMAINEN N, MCANUFF J, et al. Powered mobility interventions for very young children with mobility limitations to aid participation and positive development: the EMPoWER evidence synthesis[J]. Health Technol Assess, 2020, 24(50): 190-194.
    [17]
    潘春奇, 菅颖, 倪斌, 等. 沙库巴曲缬沙坦对射血分数降低的缺血性心肌病患者心肌损伤和炎症因子的影响[J]. 中华全科医学, 2020, 18(11): 1848-1850, 1945. doi: 10.16766/j.cnki.issn.1674-4152.001635

    PAN C Q, JIAN Y, NI B, et al. The effect of sacubitril/valsartan on myocardial injury and inflammatory factors in ischemic cardiomyopathy with reduced ejection fraction[J]. Chinese Journal of General Practice, 2020, 18(11): 1848-1850, 1945. doi: 10.16766/j.cnki.issn.1674-4152.001635
    [18]
    BIONDI B. The management of thyroid abnormalities in chronic heart failure[J]. Heart Fail Clin, 2019, 15(3): 393-398. doi: 10.1016/j.hfc.2019.02.008
    [19]
    NOURYAN C N, MORAHAN S, PECINKA K, et al. Home telemonitoring of community-dwelling heart failure patients after home care discharge[J]. Telemed J E Health, 2019, 25(6): 447-454. doi: 10.1089/tmj.2018.0099
    [20]
    ROSSIGNOL P, HERNANDEZ A F, SOLOMON S D, et al. Heart failure drug treatment[J]. Lancet, 2019, 393(10175): 1034-1044. doi: 10.1016/S0140-6736(18)31808-7
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (129) PDF downloads(7) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return